Advaxis, Inc. (NASDAQ:ADXS) has been given a $19.00 price objective by equities researchers at Cantor Fitzgerald in a report issued on Thursday. The firm currently has a “buy” rating on the biotechnology company’s stock. Cantor Fitzgerald’s target price indicates a potential upside of 196.41% from the company’s current price.

Separately, HC Wainwright set a $23.00 price target on Advaxis and gave the company a “buy” rating in a report on Monday, March 13th. Five investment analysts have rated the stock with a buy rating, Advaxis has a consensus rating of “Buy” and an average price target of $24.00.

Advaxis (NASDAQ:ADXS) traded down 4.33% on Thursday, reaching $6.41. The company had a trading volume of 848,294 shares. The stock’s 50-day moving average price is $7.58 and its 200 day moving average price is $8.20. The firm’s market capitalization is $259.36 million. Advaxis has a 52-week low of $5.70 and a 52-week high of $16.30.

COPYRIGHT VIOLATION WARNING: This news story was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/07/07/cantor-fitzgerald-reiterates-19-00-price-target-for-advaxis-inc-nasdaqadxs.html.

A number of institutional investors have recently bought and sold shares of ADXS. Tudor Investment Corp ET AL purchased a new position in Advaxis during the first quarter worth $283,000. Schwab Charles Investment Management Inc. boosted its position in Advaxis by 6.1% in the first quarter. Schwab Charles Investment Management Inc. now owns 128,504 shares of the biotechnology company’s stock worth $1,050,000 after buying an additional 7,353 shares during the last quarter. Geode Capital Management LLC boosted its position in Advaxis by 4.8% in the first quarter. Geode Capital Management LLC now owns 279,812 shares of the biotechnology company’s stock worth $2,286,000 after buying an additional 12,736 shares during the last quarter. Vanguard Group Inc. boosted its position in Advaxis by 9.2% in the first quarter. Vanguard Group Inc. now owns 1,663,010 shares of the biotechnology company’s stock worth $13,587,000 after buying an additional 139,710 shares during the last quarter. Finally, Marshall Wace North America L.P. purchased a new position in Advaxis during the first quarter worth $2,455,000. 55.06% of the stock is owned by institutional investors.

Advaxis Company Profile

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

Analyst Recommendations for Advaxis (NASDAQ:ADXS)

Receive News & Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.